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Abstract 
Recipients frequently need   blood   transfusions;   can be at risk for developing iron overload. The aim of the 
current study was to assess the iron overload and its effect on liver function tests (ALT, AST) in multiple blood 
transfusion Sudanese pediatrics patients compared with apparently healthy children. Case-control and hospital 
based study conducted in Khartoum state in Omdurman pediatric hospital during the period of  February-May 
2015, (test group n=100) 49 of them were males and 51 were females and aberrantly healthy children  (control 
group n=100) were enrolled in the study , age and gender of the test group were matched with the control group, 
blood samples obtained from each group for measuring seum level of AST,ALT by automated machine 
(mindary)  and TIBC by spectrophotometry in multiple blood transfused blood pediatric children.  The results 
show that case and controls (100 in each arm) were matched in their basic clinical data. The (mean ± SD) was 
calculated. T test or ANOVA was used for comparison between groups using SPSS v16.  
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The serum iron in patients and controls respectively were (287±235,74±17Micro g/dl), serum TIBC patients and 
controls respectively were (194±107,219 ±72 micro g/dl), serun ALT in patients and controls respectively 
were(29±36,19±8 IU/L) and serum AST in patients and controls respectively were(76±73,24±9 IU/L). Serum 
iron, ALT and AST iron were significantly increased and TIBC was decreased in pediatric multiple blood 
transfusion patients compare to healthy pediatric individual (p. value <0.000, 0.000, 0.000, 0.000) respectively. 
In this study the serum level of iron, ALT and AST were significantly increased in pediatric multiple blood 
transfusion patients, TIBC was significantly decreased in pediatric multiple blood transfusion patients  and 
significant with different sex and age of disease. 
Keywords: Iron over load; Sudanese; Blood transfusion. 
1. Introduction  
Iron is the most abundant of all essential elements; iron participates in many biochemical processes including 
cellular oxidative mechanisms and oxygen transport [1]. The major heme proteins (hemoglobin and myoglobin) 
are the most abundant iron containing compound in the body. Hemoglobin transport oxygen from the lung to the 
organ. Where it is used in respiration and myoglobin store oxygen in the skeletal muscles. Iron itself is also 
essential for transport function of the electron transport chain and, hence, respiration, it is a major component of 
several cytochromes. Where it acts as an electron acceptor or donor during oxidation phosphorilation. 
Additionally, several enzymes require iron as a cofactor including cytochrome oxidase xanthine oxidase, 
peroxidase, catalase, and NADH dehydrogenase. Transferrin is a glycoprotien that is senthesized by the liver 
and which contain two iron binding sites. Its primary function is to transport intestinally absorbed iron in the 
plasma to the sites of erythropoisis and to the liver, where excess iron is stored in hepatocytes as ferritin or 
hemosiderin. Under normal condition approximately one third of serum transfer in binding sites are bound with 
iron. Transferrin also carries iron taken up by macrophages subsequent to its release as hemoglobin from the 
breakdown of old erythrocytes. TIBC is has seen limited use since the advent of improved transferrin assay [2]. 
Ron overload can lead to end organ damage of the heart, liver, and pancreas in patients with hemochromatosis 
(3).The clinical laboratory offers several tests for the assessment of liver function. The enzymes alkaline 
phosphatase, ALT, AST, GGT, and 5-nucleotidase are helpful in the assessment of the proper functioning and 
inflammatory status of the liver [4]. Aminotransferases (ALT and AST) are two enzymes widely used to assess 
hepatocellular damage. AST is found in all tissues, especially the heart, liver, and skeletal muscles. ALT is 
present primarily in the liver to a lesser extent in kidney and skeletal muscle, making it more (liver-specific) [5]. 
2. Materials and methods 
This case-control and hospital based study conducted in Khartoum state in omdorman pediatric huspital during 
February 2015 on Sudanese multiple blood transfused blood pediatric children (test group n=100) 49 of them 
were males and 51 were females and aberrantly healthy children (control group n=100).  Permission of this 
study was obtained from to local authorities in the area of the study. An informed consent was obtained from 
each participant in the study after explaining objectives of the study. Using local antiseptic for the skin (70% 
ethanol), a sample of venous blood (3ml) was collected from each participant. The blood samples were 
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centrifuged at 4000 rpm for 5 minutes to obtain the serum. Then the serum iron and TIBC measured using 
spectrophotometer ( biosystem)  .  ALT and AST measured using automated machine (mindary). Interview with 
the test group and control were done to obtain the clinical data. A questionnaire was specifically designed to 
obtain information which help either including or excluding certain individual in or form study respectively. 
Data was presented inform in table and figure. The data collected in this study was analyzed using SPSS. The 
mean ± SD serum (iron , TIBC , ALT and AST) will calculated the test was used for comparisons. (p value 
≤0.05 is considered to be significant). 
3. Results 
100 multiple blood transfused pediatric patients were participate in this study as test group and 100 apparently 
healthy children as control group were. There was no Iron supplementation to control and test group. The two 
groups were age matched (2-15) years, serum iron, TIBC, ALT and AST were measured for all groups. The 
serum iron (mean±sd) in patients and controls respectively were (287±235, 74±17 micro.g/dl). Iron were 
significantly increased in multiple blood transfused pediatric patients compared to healthy children (p. value < 
0.050) as in table (1) 
Serum TIBC patients and controls respectively were (194±107,219 ±72 micro.g/dl). TIBC were significantly 
decreased in multiple blood transfused pediatric patients  compared to healthy children (p. value < 0.050) as in 
table (1) Among the transfused patients,80%  with iron overload. Among the 80 patients with iron overload, 
35% with elevated ALT and 68% of iron overload had elevated AST, in patients and controls respectively were 
(76±73,24±9 IU/L) as in table (1).  
Table 1: Geometric mean (SD) of Iron TIBC, ALT and AST between patient and control 
Variable Cases (n=100) Control (n=100) P –value 
Iron  micro.g/dl  287(235) 74(17) 0.000 
TIBC micro.g/dl 194(107) 219 (72) 0.000 
       
ALT  IU/L 29(36) 19(8) 0.000 
AST  IU/L 76(73) 24(9) 0.000 
    
Serum ALT in patients and controls respectively were (29±36,19±8 IU/L) (p.value<0.050) The serum ALT level 
was significant positively correlated with iron concentration as Show in figure (1)  
4. Discussion 
Iron toxicity is dose related. A study of anemic showed improved survival in patients with no iron overload [6]. 
In a study of pediatric oncology patients who underwent bone marrow transplantation, Lee and colleagues [7] 
found an increased survival rate in patients with pretransplant ferritin levels of less than 1,000 ng/mL. Another 
study of MDS revealed that patients treated with iron chelation therapy had improved survival compared with 
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patients who did not receive treatment [8]. Pediatric patients with Hodgkin disease demonstrated poor 
progression-free survival with high ferritin levels [9]. Iron overload can occur in patients who receive blood 
transfusions, particularly patients with thalassemia and sickle cell anemia. Blood transfusions in children with 
sickle cell anemia demonstrated a positive correlation between hepatic iron overload and transfusion volume 
[10]. Reducing the iron burden has been shown to improve outcomes in a number of settings.  
 
Figure 1:  scatter between Iron concentration and ALT for Patient 
 
     There was strong relation between multiple blood transfusion and iron overload   figure (2). 
 
Figure 2: scatter between Iron concentration and AST for Patient 
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Bomford and coworkers observed an increase in 5- and 10-year survival rates in patients with idiopathic 
hemochromatosis who were treated with venesection [11]. Similarly, another study of patients with hereditary 
hemochromatosis demonstrated improved survival in patients treated with phlebotomy [3]. Elevated serum iron 
levels (>108ng/mL) were associated with decreased overall survival and increased incidence of liver diseas. 
Since phlebotomy may have an important role in preventing complications from iron. 
5. Conclusion 
This study concluded that the levels of iron, ALT and AST and iron significantly increased in pediatric multiple 
blood transfusion patients and TIBC was significantly decreased in pediatric multiple blood transfusion patients 
when compared with normal healthy children. The serum concentrations of iron, ALT and AST were increased 
and TIBC was decreased in the different age and sex. 
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